SCHEMBL4972050

SCHEMBL4972050

COC(COc1nc(Cl)nc(N2CCOCC2)c1F)c1ccc(F)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 9/20 0.46
JAK3 P52333 8/20 0.46
SMN1; SMN2 Q16637 3/20 0.40
NTRK1 P04629 1/20 0.36
KCNH2 Q12809 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MTOR P42345 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4972038 0.89 JAK2 (0.49) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4972541 0.86 JAK2 (0.46) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4974714 0.83 JAK2 (0.47) JAK2JAK3SMN1; SMN2NPC1RAB9A
SCHEMBL4973163 0.83 JAK2 (0.63) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4972196 0.83 JAK2 (0.45) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4972257 0.80 JAK2 (0.59) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4972182 0.78 JAK2 (0.48) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4973170 0.78 JAK2 (0.39) JAK2JAK3MTORKDM4EABL1
SCHEMBL4972548 0.75 JAK2 (0.46) JAK2JAK3SMN1; SMN2NTRK1KCNH2
SCHEMBL4972207 0.75 JAK2 (0.64) JAK2JAK3NTRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008132502-A1 PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-11-06 WO disclosed